Market Cap | 39.31B | P/E | 12.96 | EPS this Y | 9.60% | Ern Qtrly Grth | -1.40% |
Income | 1.16B | Forward P/E | 16.14 | EPS next Y | 6.00% | 50D Avg Chg | -6.00% |
Sales | 9.67B | PEG | 3.28 | EPS past 5Y | -16.74% | 200D Avg Chg | -5.00% |
Dividend | N/A | Price/Book | 2.72 | EPS next 5Y | 3.60% | 52W High Chg | -15.00% |
Recommedations | 2.10 | Quick Ratio | 1.28 | Shares Outstanding | 145.66M | 52W Low Chg | 40.00% |
Insider Own | 0.17% | ROA | 5.19% | Shares Float | 145.13M | Beta | -0.06 |
Inst Own | 92.70% | ROE | 7.63% | Shares Shorted/Prior | 3.67M/2.68M | Price | 271.56 |
Gross Margin | 76.45% | Profit Margin | 11.98% | Avg. Volume | 1,141,158 | Target Price | 268.33 |
Oper. Margin | 32.50% | Earnings Date | Nov 6 | Volume | 1,291,128 | Change | 0.84% |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Needham | Buy | Sep 24, 24 |
Wedbush | Neutral | Sep 23, 24 |
RBC Capital | Outperform | Sep 19, 24 |
Cantor Fitzgerald | Overweight | Sep 9, 24 |
Needham | Buy | Sep 4, 24 |
Needham | Buy | Aug 19, 24 |
Mizuho | Outperform | Aug 6, 24 |
Truist Securities | Buy | Aug 5, 24 |
Needham | Buy | Aug 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Singhal Priya | Head of Development Head of Development | Feb 01 | Sell | 245.93 | 634 | 155,920 | 4,097 | 02/05/24 |
Singhal Priya | Head of Development Head of Development | Feb 01 | Option | 0 | 1,828 | 5,292 | 02/05/24 | |
Singhal Priya | Head of Development Head of Development | Dec 08 | Sell | 248 | 110 | 27,280 | 3,464 | 12/12/23 |
Singhal Priya | Head of Development Head of Development | Dec 08 | Option | 0 | 426 | 3,780 | 12/12/23 | |
Singhal Priya | Head of Development Head of Development | Sep 01 | Sell | 269.43 | 431 | 116,124 | 3,354 | 09/06/23 |
Singhal Priya | Head of Development Head of Development | Sep 01 | Option | 0 | 1,668 | 4,592 | 09/06/23 | |
Gregory Ginger | EVP, Human Resources EVP, Human Resources | Apr 28 | Sell | 300.00 | 2,681 | 804,300 | 8,483 | 05/02/23 |
Singhal Priya | Head of Development Head of Development | Apr 04 | Sell | 277.11 | 91 | 25,217 | 2,843 | 04/06/23 |
Singhal Priya | Head of Development Head of Development | Mar 28 | Sell | 270.06 | 568 | 153,394 | 2,842 | 03/30/23 |
Gregory Ginger | EVP, Human Resources EVP, Human Resources | Nov 14 | Sell | 300.11 | 5,610 | 1,683,617 | 5,711 | 12/12/22 |
ALEXANDER SUSAN H | EVP Chief Legal Off.. EVP Chief Legal Off & Corp Sec | Oct 27 | Sell | 280.70 | 5,532 | 1,552,832 | 39,396 | 10/28/22 |